Role of adjuvant therapy in intermediate-risk cervical cancer patients – Subanalyses of the SCCAN study

•We investigated the survival benefit of adjuvant therapy (AT) after radical surgery in intermediate-risk (IR) cervical cancer.•Of 692 IR cervical cancer patients in the SCANN study, 60.4% received AT (AT+) and 39.6% did not (AT−).•5-year DFS (83.2% vs. 80.3%) and OS (88.7% vs. 89.0%) rates were similar in the AT− and AT+ groups.•AT did not confer a significant survival benefit even after applying propensity score matching for confounding factors.